Is This an Obesity-Drug Success or Failure?

Before you go, we thought you'd like these...
Before you go close icon

Arena Pharmaceuticals and VIVUS are the two stocks most typically associated with obesity drugs, but diabetes-drug maker Novo Nordisk is also trying to enter this space. The company is completing phase 3 clinical trials in an attempt to get Victoza approved as a weight-loss drug for obese and overweight patients with type 2 diabetes.

After reporting data from a clinical study today, shares of Novo Nordisk fell almost 5%. In the following video, health-care analyst Max Macaluso discusses what this news means for investors and how this drug fits into the obesity-drug market.

Who will win the obesity-drug market?
Can VIVUS pick up its lagging sales and fend off the competition, or will Arena Pharmaceuticals reign supreme in the obesity space? If you're in the dark, grab copies of The Motley Fool's premium research reports on VIVUS and Arena Pharmaceuticals to stay up to date. Senior biotech analyst Brian Orelli gives investors the must-know information, including an in-depth look at the obesity market and reasons to buy and sell both stocks. Click now for an exclusive look at Arena and VIVUS -- complete with a full year of free updates -- today.


The article Is This an Obesity-Drug Success or Failure? originally appeared on Fool.com.

Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners